ClinicalTrials.gg
CompletedNCT05679830Updated Jan 11, 2023

The Effects of CBD Isolate on Menstrual-Related Symptoms

A Phase 2 interventional study of Cannabidiol in Menstrual Discomfort, sponsored by Canopy Growth Corporation. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Canopy Growth Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Sep 2020, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The goal of this open-label clinical trial is to compared two different doses for treating menstrual-related symptoms in individuals who experience regular menstrual cycles (occurring for 4-8 days every 21-28 days). The main question it aims to answer is:

(1) if there are changes in menstrual-related symptoms from baseline compared to all 3-months of cannabidiol (CBD) isolate consumption.

Participants will complete a monthly baseline measure after they stop menstruating followed by taking CBD twice daily (BID) for five days for three menstrual cycles and complete the same measures. Researchers will compare 160mg of daily CBD isolate to 320mg of CBD isolate to see if there are differential effects on menstrual-related symptoms (MRS).

02

Conditions studied

  • Menstrual Discomfort

Keywords

  • cannabidiol
  • CBD
  • menstruation
03

In context

Lead sponsor

Canopy Growth Corporation is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is at least 18 years old.
  2. Participant is willing and able to provide and participate in the study for 4 months.
  3. Participant experiences a regular period (occurring every 21-38 days and lasting between 4-8 days).
  4. Participant is diagnosed with Pre-menstrual Dysphoric Disorder or scores at least '30' on the Menstrual-Related Symptom Questionnaire
  5. Participant is willing to begin tracking their periods and menstrual symptoms for the duration of the study
  6. Participant agrees to abide by all study restrictions and comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a known history of significant allergic condition, significant to CBD, or allergic reaction to cannabis, cannabinoid medications, or of the drug product.
  2. Participant has been exposed to any drug or device \< 30 days prior to screening or plans to take another investigational drug at any time during the study.
  3. Participant has self-reported using cannabis, synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), synthetic cannabinoid receptor agonist (e.g., spice, K2), or any CBD or Tetrahydrocannabinol (THC)-containing product within 30 days of screening or during the study.
  4. Participant has a current or past primary (DSM)-5 diagnosis that the Investigator(s) determines would interfere in treatment or interfere in evaluation of the study treatment (e.g., current psychotic disorder).
  5. Participant is currently prescribed medications with known THC- or CBD- interactions (e.g., warfarin, clobazam, valproic acid, phenobarbital, Mammalian target of rapamycin (mTOR) inhibitors, oral tacrolimus).
  6. Participant is trying to get pregnant.
  7. Participant is pregnant.
  8. Participant has a history of suicide attempt in the last year.
  9. Participant endorses current suicidal plan and intent during screening.
  10. Any other significant disease or disorder which, in the opinion of the investigator, may either put the student at risk because of participation in the study, may influence the result of the study, or affect the student's ability to participate in the study.
  11. Participant has a of underweight (18 kg/m2 and below) or obese (30 kg/m2 and above).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    160mg Cannabidiol Isolate

    320mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).

    Drug: Cannabidiol

  • Experimental
    320mg Cannabidiol Isolate

    160mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).

    Drug: Cannabidiol

Interventions

  • Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.

06

What researchers measure

Primary outcomes

  1. Menstrual-Related Symptoms Questionnaire (MRSQ)

    Change in menstrual-related symptoms from baseline scores as measured by the MRSQ every cycle for three cycles. Scores range from 26-104, with higher scores representing greater severity of symptoms.

    Time frame: 1 menstrual cycle/1 month

07

Study locations

1 site
  • James Madison University
    Harrisonburg, Virginia 22801, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Sep 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2022
First posted
Jan 11, 2023
StartActual
Sep 23, 2020
Primary completionActual
Sep 23, 2021
CompletionActual
Sep 23, 2021
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05679830
Lead sponsor
Canopy Growth Corporation
Collaborators
James Madison University
Responsible party
Sponsor
First posted
Jan 11, 2023
Start date
Sep 23, 2020
Primary completion
Sep 23, 2021
Completion
Sep 23, 2021
Last update
Jan 11, 2023

Study contacts

Jessica G Irons, PhD
principal investigator · James Madison University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion